Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul B Watkins

Showing results (11-20 of 172) with videos related to

Pageof 18
Sort By:
Clinical and Translational Science|February 15, 2019
The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker InterpretationPaul B Watkins
Hepatology (Baltimore, Md.)|February 23, 2022
John R. Senior, MDMark Avigan, Paul B Watkins
Journal of Medicinal Chemistry|February 11, 2020
Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver InjuryMerrie Mosedale, Paul B Watkins
Gastroenterology|May 8, 2004
Are patients with elevated liver tests at increased risk of drug-induced liver injury?Mark W Russo, Paul B Watkins
JAMA|March 7, 2023
Moving the Needle to Reduce Acetaminophen (Paracetamol) HepatotoxicityMarc G Ghany, Paul B Watkins
Liver International : Official Journal of the International Association for the Study of the Liver|April 8, 2017
The transformation in biomarker detection and management of drug-induced liver injuryRachel J Church, Paul B Watkins
Gastroenterology|July 10, 2003
Pharmacogenetics and clinical gastroenterologyRaymond C Givens, Paul B Watkins
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2005
Role of cytochrome P450 phenotyping in cancer treatmentE Claire Dees, Paul B Watkins
Clinical Neuropharmacology|October 3, 2007
Tolcapone: an efficacy and safety review (2007)C Warren Olanow, Paul B Watkins
Experimental Biology and Medicine (Maywood, N.J.)|November 4, 2017
In silico modeling to optimize interpretation of liver safety biomarkers in clinical trialsRachel J Church, Paul B Watkins
Pageof 18

Showing results (11-20 of 172) with videos related to

Sort By:
Pageof 18
Clinical and Translational Science|February 15, 2019
The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker InterpretationPaul B Watkins
Hepatology (Baltimore, Md.)|February 23, 2022
John R. Senior, MDMark Avigan, Paul B Watkins
Journal of Medicinal Chemistry|February 11, 2020
Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver InjuryMerrie Mosedale, Paul B Watkins
Gastroenterology|May 8, 2004
Are patients with elevated liver tests at increased risk of drug-induced liver injury?Mark W Russo, Paul B Watkins
JAMA|March 7, 2023
Moving the Needle to Reduce Acetaminophen (Paracetamol) HepatotoxicityMarc G Ghany, Paul B Watkins
Liver International : Official Journal of the International Association for the Study of the Liver|April 8, 2017
The transformation in biomarker detection and management of drug-induced liver injuryRachel J Church, Paul B Watkins
Gastroenterology|July 10, 2003
Pharmacogenetics and clinical gastroenterologyRaymond C Givens, Paul B Watkins
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2005
Role of cytochrome P450 phenotyping in cancer treatmentE Claire Dees, Paul B Watkins
Clinical Neuropharmacology|October 3, 2007
Tolcapone: an efficacy and safety review (2007)C Warren Olanow, Paul B Watkins
Experimental Biology and Medicine (Maywood, N.J.)|November 4, 2017
In silico modeling to optimize interpretation of liver safety biomarkers in clinical trialsRachel J Church, Paul B Watkins
Pageof 18